Stryker Q3 Sales Up 7.7% but Management Says Results Fell Short; 2026 Guidance Reset
SYK is trading near its 52-week low of $267 (9.6% above the low).
Summary
Stryker posted 7.7% organic growth and $3.52 adjusted EPS but said the quarter fell short of internal expectations, and reset full-year 2026 guidance to 6.5%-7.0% organic growth and $14.80-$14.90 adjusted EPS. The board also added $3.0 billion to the share repurchase program.
Key Events · Earnings and Guidance · SYK
-
Q3 Sales Grow 7.7%, Below Plan
Net sales of $6.5 billion rose 7.7% on both a reported and organic basis, driven by unit volume; MedSurg and Neurotechnology grew 9.2% while Orthopaedics grew 5.7%. CEO Kevin Lobo said the result 'did fall short of our expectations.'
-
Adjusted EPS $3.52, Reported $1.96
Adjusted EPS rose 10.3% to $3.52 and adjusted operating margin expanded 60 bps to 26.2%. Reported EPS fell 11.7% to $1.96, weighed by a $293 million goodwill impairment ($0.76 per share) and $153 million of structural optimization charges.
-
2026 Guidance Reset Lower
Full-year 2026 guidance now calls for organic net sales growth of 6.5% to 7.0% and adjusted EPS of $14.80 to $14.90, including a modestly positive pricing impact and slightly favorable FX.
-
Buyback Raised by $3.0 Billion
Stryker repurchased $1.0 billion of stock in Q3 2026, and in October 2026 the board approved a $3.0 billion increase to the existing repurchase program.
Analysis · SYK · Industrial Applications And Services
What moves the stock here is not the 7.7% organic growth to $6.5 billion or the 10.3% rise in adjusted EPS to $3.52, but the CEO's explicit admission that the quarter 'did fall short of our expectations.' The gap between reported and adjusted earnings is wide: reported EPS fell 11.7% to $1.96 after a $293 million goodwill impairment and $153 million of structural optimization charges, so the headline adjusted number depends on $0.76 per share of impairment being excluded. Guidance was reset to 6.5%-7.0% organic growth and $14.80-$14.90 adjusted EPS, and the board added $3.0 billion to the buyback after $1.0 billion of repurchases in the quarter — a large authorization that supports the share count but does not fix the demand shortfall management just acknowledged.
How filings like this one have moved
In the 30 days to Oct 29, 2026, 30.9% of the 1649 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.02%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SYK was trading at $292.69 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $119.6B. The 52-week trading range was $267.00 to $389.33. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.